Studies that used in vitro and in vivo models show that LRGT improves AD pathological features, such as amyloid and tau pathologies, inflammation, or oxidative stress (McClean et al., 2011; Chen et al., 2017; Duarte et al., 2020; Jantrapirom et al., 2020), and cognitive alterations (Chen et al., 2017; Batista et al., 2018) in AD. The gene discussed is MAPT; the disease is Alzheimer disease.